BD (Becton, Dickinson and Company) and Ypsomed are fortifying their existing partnership by developing a 5.5 mL version of the BD Neopak XtraFlow Glass Prefillable Syringe. The product is intended to be fully compatible with Ypsomed’s YpsoMate 5.5 autoinjector platform, thereby expanding options for companies and patients that require large‑volume subcutaneous self‑injections.

The new 5.5mL BD Neopak XtraFlow Glass Prefillable Syringe leverages BD advanced technologies— including a shorter, 8-millimeter needle and thinner wall cannulas—to support the delivery of higher volume and viscosity medicines. These enhancements should improve injection time and optimize flow, both of which are common challenges with large-volume biologics and enable drug developers to move beyond the limitations of standard syringe offerings.

“This next-generation syringe is a direct response to the growing demand for patient-friendly solutions in the high-dose biologics space,” said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. “By combining BD’s expertise in drug delivery with Ypsomed’s leadership in autoinjector platforms, we are helping to simplify self-injection for patients managing complex conditions.”

Large‑volume (greater than 1 mL) subcutaneous biologics injections are increasingly common in areas such as oncology, autoimmune diseases, rare diseases, and metabolic disorders. Ypsomed’s YpsoMate 5.5, introduced in 2022, was developed to meet this need; it offers an ergonomic design, intuitive two‑step activation, and clear feedback to support patient confidence and ease of use.

The new BD Neopak XtraFlow 5.5mL Glass Prefillable Syringe is designed to further enhance the YpsoMate 5.5 platform by maximizing flow efficiency and reducing injection time,* which are critical factors as dosing volumes and drug viscosities continue to rise.

“Ypsomed and BD, in close collaboration with our pharmaceutical partners, are expanding the subcutaneous delivery design space to accommodate high-dose therapies, both volume and viscosity,” Ypsomed Chief Business Officer Ulrike Bauer stated. “These partnerships are critical as we jointly drive the future of high-dose biopharmaceutical delivery.”

BD and Ypsomed have a strong history of collaboration, beginning with the BD Neopak XtraFlow 2.25mL Glass Prefillable Syringe and YpsoMate 2.25 autoinjector. This combination demonstrated improved flow and optimized injection times across various drug viscosities, including up to 70cP.¹ The new 5.5 mL version builds on this success, aiming to accelerate and de-risk development of combination products and reduce time-to-market.

The BD Neopak XtraFlow 5.5mL Glass Prefillable Syringe is currently in development and will undergo comprehensive testing to ensure compatibility with the YpsoMate 5.5 platform. Syringe samples for feasibility studies are expected to be available in the middle of this year. Within the same timeline, Ypsomed will expand the YpsoMate 5.5 platform and integrate the BD Neopak XtraFlow 5.5mL Glass Prefillable Syringe.

BD is one of the world’s largest global medical technology companies and is advancing health by improving medical discovery, diagnostics, and care delivery. The company develops technology, services, and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its more than 70,000 employees help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease, and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations worldwide to address challenging global health issues. By working in close collaboration with customers, BD helps enhance outcomes, lower costs, increase efficiencies, improve safety, and expand healthcare access.

Ypsomed develops and manufactures injection systems for the self-administration of liquid medication. As the partner of pharmaceutical and biotech companies for more than 40 years, Ypsomed provides tailored selfcare solutions to meet specific needs. The company’ offers a’s product portfolio includes pens, autoinjectors, and on-body devices. Ypsomed is headquartered in Burgdorf, Switzerland, operates a global network of manufacturing facilities, and employs more than 2,000 workers worldwide.

* When compared to 12.7 mm special thin wall needle

Reference
1 Blaser, T. & Douaire, M. (May 20, 2025). Optimising High‑Dose Delivery: Syringe–Autoinjector Integration, Injection Time and Performance. ONdrugDelivery, Issue 172, pp. 32–37